Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with University of Georgia
Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today the establishment of a collaborative drug discovery program with Dr. Geert-Jan Boons' laboratory located in the Complex Carbohydrate Research Center at the University of Georgia. This program is focused on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.